The current delivery of Polynucleotides with Micro needling for practitioners in the United States versus Europe and Asia. By Deborah Winter, RN.
Microneedling combined with the application of Polydeoxyribonucleotide (PDRN) has emerged as an increasingly popular treatment modality in the United States.
PDRN is a bioactive compound derived from DNA fragments extracted from salmon sperm. It has exhibited significant anti-inflammatory and skin-brightening effects by inhibiting melanin production and fostering tissue repair. Numerous preclinical and clinical studies have validated the diverse properties of PDRN, including its anti-inflammatory, anti-melanogenic, regenerative, tissue damage preventive, anti-ulcerative, and wound healing capabilities (Kim et al., 2022; Sun et al., 2023).
Microneedling devices, such as the SkinPen™, create micro-channels at a frequency of 1,600 per second, stimulating the immune system to enhance blood circulation, and initiate the formation of new tissue. During the proliferation phase, a network of new blood vessels is formed, allowing the micro-wounds to heal with granulation cells rich in collagen proteins. Finally, during the remodeling phase, the micro-wounds are reconstructed with fresh dermal tissue and blood vessels composed of collagen and elastin proteins (Crown Aesthetics, 2025).
Recent studies have underscored the potential of microneedling to improve the transdermal delivery of various therapeutics by bypassing the stratum corneum and facilitating direct access to the vascularized dermis. Notably, this technique has been shown to significantly expand the follicular infundibulum by 47%, potentially enhancing the penetration of medications through the skin barrier (Litchman G, Nair PA, Badri T, et al.).
When these two treatment modalities are employed in tandem, the micro-channels created by microneedling facilitate the penetration of PDRN into the deeper layers of the skin. It is important to note that while PDRN injections are approved for use in Europe and are preferred in that context, the FDA has yet to authorize its injectable form in the United States.
Practitioners in this region primarily rely on microneedling to administer PDRN, which poses particular challenges in the delicate under-eye area due to the proximity of blood vessels to the skin's surface. Expertise in needle precision is crucial.
For the past two years, I have dedicated myself to mastering this technique and have traveled back to London multiple times to refine my skills further in preparation for offering this advanced treatment. I am committed to providing PDRN microneedling services upon FDA approval of Nutrophil, the leading manufacturer from Italy, which will enhance the options available for effective skin rejuvenation.
Khan, A., Wang, G., Zhou, F., Gong, L., Zhang, J., Qi, L., & Cui, H. (2022). Polydeoxyribonucleotide: A promising skin anti-aging agent. Chinese Journal of Plastic and Reconstructive Surgery, 4(4), 187-193.
Litchman G, Nair PA, Badri T, et al. Microneedling. [Updated 2022 Sep 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459344/